Below you can find some frequently asked questions and answers about treatment with ALSAVIN Family. If you would like more detailed information or have a specific question, please contact us or a healthcare professional.
ALSAVIN Family is a hyaluronic acid intra-articular injection system which is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non pharmacologic therapy and simple analgesics.
Osteoarthritis (OA) is the most common type of joint disease1. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it may cause losing functional ability; some people are no longer able to do daily tasks or work. Risk factors include excess weight, family history, age and previous injury (i.e., an anterior cruciate ligament, or ACL tear).
Hyaluronic acid, also called hyaluronan or hyaluronate is a gel-like substance that is naturally present throughout the human body. In the joints, natural hyaluronic acid has several functions, including lubrication, growth of cartilage and bone, reducing inflammation. In the joints and in the rest of the body, hyaluronic acid also acts like a moisturizer, keeping tissues hydrated.
Hyaluronic acid can be commercially manufactured using bacterial fermentation or extracted from certain animal tissues, typically rooster combs. Hyaluronic acid is more commonly extracted from bacterial fermentation than rooster combs. The bacterial extract produces higher yield, better quality, and has a lower risk of contamination2.
In patients with osteoarthritis the viscoelasticity of the synovial fluid is significantly impaired, causing the mechanical stress on the joint and the breakdown of the articular cartilage to greatly increase resulting in limited and painful joint movement3.
Hyaluronic acid injections may reduce or relieve inflammation caused by wearing of the cartilage and bone in osteoarthritic joints. The injected gel helps to restore lubrication and also induces the growth of new cartilage and bone tissue in these joints. Osteoarthritis of the knee, shoulder, ankle, hip and thumb joints may be treated with hyaluronic acid injections4-5.
ALSAVIN Family is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non pharmacologic therapy and simple analgesics6.
Please ask your doctor for detailed information if ALSAVIN Family is right choice for you and discuss your treatment options.
It is recommended to apply ALSAVIN 1.0% with 3-5 injections one week apart and ALSAVIN Supra 1.6% with 1-3 injections one week apart. ALSAVIN One 2.0% is 1-2 injections7. Depending on the patient’s condition or the doctor’s suggestion, the treatment cycles may be repeated every six months.
This procedure is usually done in a doctor’s office and performed by an orthopedic physician. Some rheumatologists and primary care doctors may also provide this treatment. ALSAVIN 1.0%, ALSAVIN Supra 1.6% and ALSAVIN One 2.0% intra-articular injections are given directly into the knee joint capsule. ALSAVIN IAIs should only be used by a physician for intra-articular injection7.
- The patient either lies on his or her back with the knee straight or sits upright with the knee bent, this position would depend on the doctor’s preferred approach to insert the needle into the knee capsule.
- The knee is wiped down with a disinfectant, such as alcohol or iodine.
- The patient is asked to relax the leg muscles; this will facilitate a successful injection and may also make the injection less painful.
- The doctor may administer a local anesthetic, such as lidocaine, to numb the area.
- If the knee is swollen with excess fluid, the doctor may aspirate this fluid with a needle and syringe.
- Using a new, sterile syringe, the doctor will inject the hyaluronic acid on one side of the knee.
- The injection area will be cleaned and bandaged.
- The patient will be told to straighten and bend the knee several times to help spread the material throughout the knee joint.
Injection pain can vary from person to person. The doctor may discuss with the patient and offer options to relieve any possible discomfort. The doctor may administer a local anesthetic, such as lidocaine, to numb the knee before the injection is given.
Injections may be given in both knees simultaneously according to the physician’s recommendations7. ALSAVIN IAIs are intended for single use only. The reuse of the product creates a potential infection risks for patients or users8.
In order to avoid overuse of treated joints patients should be advised to relative rest (but no immobilization) for 24h after each injection8. It is recommended that an ice–pack be placed on the joint undergoing treatment for 5 -10 minutes in order to prevent pain and swelling7.
Following the use ALSAVIN IAIs, patients may experience local symptoms in the joint being treated (pain, sensation of heat, redness and swelling). The following adverse events have been reported for similar products: mild or moderate arthralgia, in rare cases skin rash, aseptic joint effusions, pruritus and muscular cramps. Further adverse events that have been observed in very rare cases are: allergic reactions, anaphylactic shock, hemarthrosis, phlebitis, pseudosepsis, severe acute inflammatory reaction (SAIR), nasopharyngitis, joint stiffness, tendonitis, bursitis, fever and myalgia9.
1 What Is Arthritis? Types of Arthritis, Degenerative Arthritis
2 Carmen G. Boeriu, Jan Springer, Floor K. Kooy, Lambertus A. M. van den Broek, and Gerrit Eggink, “Production Methods for Hyaluronan,” International Journal of Carbohydrate Chemistry, vol. 2013, Article ID 624967, 14 pages, 2013.
3 ALSAVIN Instruction For Use, Properties and Efficacy, Alsanza Medizintechnik und Pharma GmbH, 2020
4. Hunter DJ. Viscosupplementation for Osteoarthritis of the
Knee. Jarcho JA, ed. New England Journal of Medicine. 2015;372(11):1040-1047. doi:10.1056/nejmct1215534
5 Henrotin Y, Raman R, Richette P, et al. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Seminars in Arthritis and Rheumatism. 2015;45(2):140-149.
6 ALSAVIN Instruction For Use, Indications, Alsanza Medizintechnik und Pharma GmbH, 2020.
7 ALSAVIN Instruction For Use, Dosage and Administration, Alsanza Medizintechnik und Pharma GmbH, 2020.
8 ALSAVIN Instruction For Use, Warnings and Precautions, Alsanza Medizintechnik und Pharma GmbH, 2020.
9 ALSAVIN Instruction For Use, Side Effects, Alsanza Medizintechnik und Pharma GmbH, 2020.